For more than 125 years, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for the world’s most challenging diseases. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world – including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. MSD has been operating in Russia since 1991 with a focus on delivering innovative medicines and vaccines, cooperation with local manufacturers and leading medical institutions, clinical research programs, as well as medical education and information support. We use our global expertise to contribute to the development of healthcare and pharmaceutical industry in Russia.
For more information, visit www.msd.ru
GSK was founded more than 300 years ago and entered the Russian market at the end of the 1980s.
More than 60 pharmaceutical medicines and 14 paediatric and adult vaccines have been registered in Russia by GSK for the treatment of HIV, respiratory and infectious diseases, and diseases of the central nervous system.
GSK was the first company in Russia to introduce a vaccine against hepatitis B (1989), hepatitis A (1995), chickenpox (2008) and a number of combined paediatric vaccines.
In the last 10 years, GSK has invested more than 6.5 billion roubles in R&D in Russia. More than 30 international multicentre clinical studies are currently being conducted in Russia at 250 clinical centres in 35 cities across the country, with the involvement of nearly 750 medical researchers.
Since 1997, GSK has been developing its own vaccine production facilities in Russia, with more than 37 million vaccine doses produced.
In 2019, GSK successfully completed a project to localise the full-cycle manufacturing of Dolutegravir, a drug for the treatment of HIV, at the Servier Rus pharmaceutical plant in New Moscow.
The company portfolio includes more than 55 approved products, 10 of which are biologics. Forty products are currently in development: biologics, small molecules, gene and cell therapy drugs. Today BIOCAD is focused on developing original drugs – next-in-class and first-in-class – for the treatment of immuno-oncology, hematology and autoimmune diseases.
BIOCAD has international offices and subsidiaries in 8 countries. Its products are marketed in 15 countries from Latin America to Africa and Southeast Asia and approval processes are ongoing in over 30 countries worldwide. Starting from 2021, the company will launch its original and biosimilar products in Europe and plans to enter the Chinese market in 2022.
